Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST266 in partial-thickness burns
NCT00886470Phase 2Terminated
- Sponsor
- Noveome Biotherapeutics
- Start
- Jun 2009
- Primary completion
- Mar 2010
- Modality
- Cytokines & Interferons, Hormones & Growth Factors
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ST266 in partial thickness burn (3 arms), sponsored by Noveome Biotherapeutics. Primary endpoint: Percentage of wound epithelialized at 21 days. Started Jun 2009; status: terminated.
02
Drugs
ST266
03
Conditions
partial thickness burn
Beyond the preview
Go deeper on NCT00886470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00886470.